New Immunotherapy-Chemotherapy Combinations Approved for Advanced Endometrial Cancer

FDA Approves Pembrolizumab and Durvalumab Combinations, Offering Hope for Patients with Advanced Endometrial Cancer

Topline:

The FDA has approved two new immunotherapy-chemotherapy combinations for patients with primary advanced or recurrent endometrial cancer. Pembrolizumab and durvalumab, used alongside standard chemotherapy, have significantly improved progression-free survival in clinical trials. These advancements provide new hope for patients and valuable insig…